SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer
- PMID: 25070488
- DOI: 10.1007/s13277-014-2372-4
SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer
Abstract
Lung cancer is one of the leading causes of cancer-related death in developed countries. Despite decades of intensive efforts to comate this malignant disease, the prognosis of lung cancer remains unfavorable and is especially poor in advanced non-small cell lung cancer (NSCLC). Accumulating evidence indicate that one of the main causes of the poor outcome in NSCLC treatment is the innate resistance of NSCLC patients to anticancer drugs. However, the mechanism underling NSCLC development and drug resistance is not fully understood. Here we show that the mitochondrial class III NAD(+)-dependent deacetylase SIRT5 is overexpressed in human NSCLC and high expression of SIRT5 predicts poor survival. SIRT5 knockdown represses lung cancer cell growth and transformation in vitro and in vivo. Furthermore, we find that SIRT5 knockdown makes lung cancer cells more sensitive to drug (cis-diamminedichloroplatinum [CDDP], 5-fluorouracil [5-FU] or bleomycin) treatment in vitro and in vivo. Mechanically, we identify Nrf2, which is a core transcription factor for lung cancer growth and drug resistance, as a target of SIRT5. SIRT5 mRNA level is positively correlated with the expression of Nrf2 in lung cancer tissues and SIRT5 knockdown reduces the expression of Nrf2 and its downstream drug-resistance genes. Taken together, our findings implicate that SIRT5 as a protein responsible for growth and drug resistance in human NSCLC, and SIRT5 may serve as a potential prognostic factor and drug target for intervention.
Similar articles
-
Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237. J Thorac Oncol. 2013. PMID: 23287853
-
Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.Sci Rep. 2014 Oct 6;4:6527. doi: 10.1038/srep06527. Sci Rep. 2014. PMID: 25284075 Free PMC article.
-
CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.Oncol Rep. 2017 Feb;37(2):921-928. doi: 10.3892/or.2016.5289. Epub 2016 Dec 2. Oncol Rep. 2017. PMID: 27922681
-
Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.Surg Oncol. 2015 Dec;24(4):329-34. doi: 10.1016/j.suronc.2015.09.001. Epub 2015 Sep 14. Surg Oncol. 2015. PMID: 26690822 Review.
-
Emerging role of sirtuins in non‑small cell lung cancer (Review).Oncol Rep. 2024 Oct;52(4):127. doi: 10.3892/or.2024.8786. Epub 2024 Aug 2. Oncol Rep. 2024. PMID: 39092574 Free PMC article. Review.
Cited by
-
Sirtuins and the Metabolic Hurdles in Cancer.Curr Biol. 2015 Jun 29;25(13):R569-83. doi: 10.1016/j.cub.2015.05.012. Curr Biol. 2015. PMID: 26126285 Free PMC article. Review.
-
Sirtuin 5 is Anti-apoptotic and Anti-oxidative in Cultured SH-EP Neuroblastoma Cells.Neurotox Res. 2017 Jan;31(1):63-76. doi: 10.1007/s12640-016-9664-y. Epub 2016 Aug 30. Neurotox Res. 2017. PMID: 27577743
-
Mitochondrial Sirtuins in Cancer: Emerging Roles and Therapeutic Potential.Cancer Res. 2016 May 1;76(9):2500-6. doi: 10.1158/0008-5472.CAN-15-2733. Epub 2016 Apr 20. Cancer Res. 2016. PMID: 27197261 Free PMC article. Review.
-
Emerging Roles for SIRT5 in Metabolism and Cancer.Antioxid Redox Signal. 2018 Mar 10;28(8):677-690. doi: 10.1089/ars.2017.7264. Epub 2017 Oct 26. Antioxid Redox Signal. 2018. PMID: 28707979 Free PMC article.
-
Sirtuins as Important Factors in Pathological States and the Role of Their Molecular Activity Modulators.Int J Mol Sci. 2021 Jan 10;22(2):630. doi: 10.3390/ijms22020630. Int J Mol Sci. 2021. PMID: 33435263 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials